Klin Farmakol Farm. 2024;38(4):145-149 | DOI: 10.36290/far.2024.022

Pharmacological profile of fosfomycin

Jitka Rychlíčková
Farmakologický ústav, Lékařská fakulta, Masarykova univerzita, Brno
Fakultní nemocnice u sv. Anny v Brně, Brno

Fosfomycin, an antibiotic discovered in 1969, is experiencing a renaissance, parti­cularly in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. The combination of its unique mechanism of action, broad spectrum of activity, favourable level of resistance, good tissue penetration and low incidence of adverse events makes it a valuable therapeutic alternative. The aim of this article is to summarize the main pharmacological characteristics of fosfomycin with emphasis on its intravenous form.

Keywords: fosfomycin, pharmacokinetics, pharmacodynamics, PK/PD characteristics, safety, dosage.

Accepted: January 23, 2025; Published: February 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rychlíčková J. Pharmacological profile of fosfomycin. Klin Farmakol Farm. 2024;38(4):145-149. doi: 10.36290/far.2024.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. PubChem. Fosfomycin [Internet]. [citován 29. srpen 2024]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/446987.
    2. Cao Y, Peng Q, Li S, et al. The intriguing biology and chemistry of fosfomycin: the only marketed phosphonate antibiotic. RSC Adv. 2019;9(72):42204-42218. Go to original source... Go to PubMed...
    3. Dijkmans AC, Ortiz Zacarías NV, Burggraaf J, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017;6(4):24. Go to original source... Go to PubMed...
    4. Trinh TD, Smith JR, Rybak MJ. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019;39(11): 1077-1094. Go to original source... Go to PubMed...
    5. Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-347. Go to original source... Go to PubMed...
    6. Tran MT. New ways of using old antibiotics in pediatrics: Focus on fosfomycin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(7):705-712. Go to original source... Go to PubMed...
    7. Pfausler B, Spiss H, Dittrich P, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. Journal of Antimicrobial Chemotherapy. 2004;53(5):848-852. Go to original source... Go to PubMed...
    8. König C, Martens-Lobenhoffer J, Czorlich P, et al. Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study. Ann Clin Microbiol Antimicrob. 2023;22:29. Go to original source... Go to PubMed...
    9. Lenzi A, Saccani B, Di Gregorio M, et al. Fosfomycin-Containing Regimens for the Treatment of Central Nervous System Infections in a Neonatal Intensive Care Unit: A Case Series Study. Antibiotics (Basel). 2024;13(7):667. Go to original source... Go to PubMed...
    10. Tsegka KG, Voulgaris GL, Kyriakidou M, et al. Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence. Expert Rev Anti Infect Ther. 2020;18(7):657-668. Go to original source... Go to PubMed...
    11. Roussos N, Karageorgopoulos DE, Samonis G, et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. International Journal of Antimicrobial Agents. 2009;34(6):506-515. Go to original source... Go to PubMed...
    12. Candel FJ, David MM, López JB. New perspectives for reassessing fosfomycin: applicability in current clinical practice. Rev Esp Quimioter. 2019;32(Suppl 1):1-7.
    13. Antonello RM, Di Bella S, Maraolo AE, et al. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies. Eur J Clin Microbiol Infect Dis. 2021;40(6):1117-1126. Go to original source... Go to PubMed...
    14. Busse D, Simon P, Petroff D, et al. High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients. Antimicrob Agents Chemother. 2022;66(6):e02302-21. Go to original source... Go to PubMed...
    15. Rodríguez-Gascón A, Canut-Blasco A. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin. Rev Esp Quimioter. 2019;32(Suppl 1):19-24.
    16. Asuphon O, Montakantikul P, Houngsaitong J, et al. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation. International Journal of Infectious Diseases. 2016;50:23-29. Go to original source... Go to PubMed...
    17. Traunmüller F, Popovic M, Konz KH, et al. A Reappraisal of Current Dosing Strategies for Intravenous Fosfomycin in Children and Neonates. Clin Pharmacokinet. 2011;50(8):493-503. Go to original source... Go to PubMed...
    18. CLSI. MIC Breakpoint Table [Internet]. cit. 15-12-2024. Available from: https://clsi.org/media/wxwfzvpd/part_b_clsi_vs_fda-breakpoints.xlsx.
    19. EUCAST. EUCAST guidance on use of fosfomycin i.v. breakpoints [on-line]. cit. 15-12-2024. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Use_of_fosfomycin_iv_breakpoints_General_advice_20240528.pdf.
    20. WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book [Internet]. cit. 29-082024. Available from: https://www.who.int/publications/i/item/9789240062382.
    21. SÚKL. Fomicyt [on-line]. cit. 29-08-2024. Available from: https://prehledy.sukl.cz/prehledy/v1/dokumenty/11675.
    22. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-62. Go to original source... Go to PubMed...
    23. Pipitone G, Di Bella S, Maraolo AE, et al. Intravenous Fos­fomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections. Antibiotics (Basel). 2023;12(12):1653. Go to original source... Go to PubMed...
    24. Tsegka KG, Voulgaris GL, Kyriakidou M, et al. Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Rev Anti Infect Ther. 2022;20(1):33-43. Go to original source... Go to PubMed...
    25. SÚKL. Urifos [Internet]. cit. 29_08-2024. Available from: https://prehledy.sukl.cz/prehledy/v1/dokumenty/13159.
    26. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732-739. Go to original source... Go to PubMed...
    27. Merative Micromedex® [Internet]. cit. 20-07-2023. Micromedex® Drug Interactions Results. Available from: http://micromedex.fnusa.cz/micromedex2/librarian/PFDefault/evidencexpert.ShowDrugInteractionsResults.
    28. Kollu K, Bas A, Gok F, et al. Effect of fosfomycin-induced hypernatremia on patients' hospital stay length and survival. Ir J Med Sci. 2024;193(5):2453-2459. doi: 10.1007/s11845-024-03718. Go to original source...
    29. Florent A, Chichmanian RM, Cua E, et al. Adverse events associated with intravenous fosfomycin. International Journal of Antimicrobial Agents. 2011;37(1):82-83. Go to original source... Go to PubMed...
    30. Al Jalali V, Matzneller P, Wulkersdorfer B, et al. Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers. Antimicrob Agents Chemother. 2020;65(1):e01375-20. Go to original source... Go to PubMed...
    31. Ashley C, Dunleavy A. The Renal Drug Handbook [Internet]. 5th ed. CRC Press; 2019 [citován 3. leden 2023]. Available from: https://www.medicinainterna.net.pe/sites/default/files/The_Renal_Drug_Handbook_The_Ultimate.pdf. Go to original source...
    32. Mensa J, Barberán J, Soriano A, et al. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. Rev Esp Quimioter. 2018;31(1):78-100.
    33. Gatti M, Pea F. Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics. Clin Pharmacokinet. 2021;60(10):1271-1289. Go to original source... Go to PubMed...
    34. Parker S, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International Journal of Antimicrobial Agents. 2013;42(4):289-293. Go to original source... Go to PubMed...
    35. Baltogianni M, Dermitzaki N, Kosmeri C, et al. Reintroduction of Legacy Antibiotics in Neonatal Sepsis: The Special Role of Fosfomycin and Colistin. Antibiotics (Basel). 2024;13(4):333. Go to original source... Go to PubMed...
    36. Taylor CG, Mascarós E, Román J, et al. Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin. Chemotherapy. 1977;23 Suppl 1:310-314. Go to original source... Go to PubMed...
    37. Keating GM. Fosfomycin Trometamol: A Review of Its Use as a Single-Dose Oral Treatment for Patients with Acute Lower Urinary Tract Infections and Pregnant Women with Asymptomatic Bacteriuria. Drugs. 2013;73(17):1951-1966. Go to original source... Go to PubMed...
    38. Lebedevs T. Fosfomycin and breastfeeding. Aust Prescr. 2020;43(4):113. Go to original source... Go to PubMed...
    39. Bouchet JL, Quentin C, Albin H, et al. Pharmacokinetics of fosfomycin in hemodialyzed patients. Clin Nephrol. 1985;23(5):218-221.
    40. Dalet F, Bade G, Roda M. Pharmacokinetics of fosfomycin during hemodialysis. Chemotherapy. 1977;23 Suppl 1:2106. Go to original source... Go to PubMed...
    41. Schmidt JJ, Bode-Böger SM, Wilhelmi M, et al. Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing. Journal of Anti­microbial Chemotherapy. 2016;71(9):2673-2674. Go to original source... Go to PubMed...
    42. Gerecke LKV, Schmidt JJ, Hafer C, et al. Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy. Journal of Antimicrobial Chemotherapy. 2022;77(1):169-173. Go to original source... Go to PubMed...
    43. Gattringer R, Meyer B, Heinz G, et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemo­filtration. J Antimicrob Chemother. 2006;58(2):367-371. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.